Seelos Therapeutics, Inc.
SEELQ
$0.0005
$0.000.00%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.01M | 1.97M | 2.20M | 1.55M | 1.14M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.01M | 1.97M | 2.20M | 1.55M | 1.14M |
| Cost of Revenue | 34.40M | 41.88M | 44.03M | 72.53M | 72.53M |
| Gross Profit | -32.38M | -39.91M | -41.82M | -70.98M | -71.39M |
| SG&A Expenses | 11.39M | 11.62M | 12.59M | 12.59M | 12.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.82M | 39.60M | 42.70M | 52.30M | 56.70M |
| Operating Income | -29.81M | -37.62M | -40.50M | -50.75M | -55.55M |
| Income Before Tax | 4.09M | -27.12M | -37.88M | -51.09M | -81.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 4.09 | -27.12 | -37.88 | -51.09 | -81.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.09M | -27.12M | -37.88M | -51.09M | -81.19M |
| EBIT | -29.81M | -37.62M | -40.50M | -50.75M | -55.55M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 181.92 | -687.54 | -1.12K | -1.69K | -2.69K |
| Normalized Basic EPS | 205.19 | -221.25 | -502.85 | -853.65 | -1.51K |
| EPS Diluted | -569.17 | -1.43K | -1.86K | -2.43K | -2.69K |
| Normalized Diluted EPS | 182.29 | -244.15 | -525.74 | -876.54 | -1.51K |
| Average Basic Shares Outstanding | 347.70K | 225.40K | 153.10K | 126.80K | 119.40K |
| Average Diluted Shares Outstanding | 351.60K | 228.80K | 156.50K | 130.20K | 119.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |